APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gastric Motility Disorder Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Gastric Motility Disorder Drug Market Outlook and Growth Opportunities 2026

19 December 2025193 pages

Choose your research edition.

Industry ResearchGastric Motility Disorder Drug Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Gastric Motility Disorder Drug Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Gastric Motility Disorder Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gastric Motility Disorder Drug Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Gastric Motility Disorder Drug Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Gastric Motility Disorder Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Gastric Motility Disorder Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Gastric Motility Disorder Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Gastric Motility Disorder Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Gastric Motility Disorder Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Gastric Motility Disorder Drug market include Theravance, Inc., Targacept, Inc., Helsinn Healthcare S.A., Concert Pharmaceuticals, Inc. and ChironWells GmbH, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Gastric Motility Disorder Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gastric Motility Disorder Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gastric Motility Disorder Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Gastric Motility Disorder Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Gastric Motility Disorder Drug Segment by Company

Theravance, Inc.

Targacept, Inc.

Helsinn Healthcare S.A.

Concert Pharmaceuticals, Inc.

ChironWells GmbH

Gastric Motility Disorder Drug Segment by Type

Ipamorelin

Velusetrag

TD-8954

Others

Gastric Motility Disorder Drug Segment by Application

Hospital

Clinic

Home Use

Gastric Motility Disorder Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Gastric Motility Disorder Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Gastric Motility Disorder Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Gastric Motility Disorder Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Gastric Motility Disorder Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastric Motility Disorder Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gastric Motility Disorder Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastric Motility Disorder Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Gastric Motility Disorder Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gastric Motility Disorder Drug industry.

Chapter 3: Detailed analysis of Gastric Motility Disorder Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Gastric Motility Disorder Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Gastric Motility Disorder Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Gastric Motility Disorder Drug Industry Trends Table 2. Gastric Motility Disorder Drug Industry Drivers Table 3. Gastric Motility Disorder Drug Industry Opportunities and Challenges Table 4. Gastric Motility Disorder Drug Industry Restraints Table 5. Global Gastric Motility Disorder Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Gastric Motility Disorder Drug Revenue Share by Company (2021-2026) Table 7. Global Gastric Motility Disorder Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Gastric Motility Disorder Drug Sales Volume Share by Company (2021-2026) Table 9. Global Gastric Motility Disorder Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Gastric Motility Disorder Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Gastric Motility Disorder Drug Key Company Manufacturing Base & Headquarters Table 12. Global Gastric Motility Disorder Drug Company, Product Type & Application Table 13. Global Gastric Motility Disorder Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Gastric Motility Disorder Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Ipamorelin Table 18. Significant Companies of Velusetrag Table 19. Significant Companies of TD-8954 Table 20. Significant Companies of Others Table 21. Global Gastric Motility Disorder Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Gastric Motility Disorder Drug Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Gastric Motility Disorder Drug Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Gastric Motility Disorder Drug Sales Volume Share by Type (2021-2026) Table 25. Global Gastric Motility Disorder Drug Sales Volume Share by Type (2027-2032) Table 26. Global Gastric Motility Disorder Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Gastric Motility Disorder Drug Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Gastric Motility Disorder Drug Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Gastric Motility Disorder Drug Sales Value Share by Type (2021-2026) Table 30. Global Gastric Motility Disorder Drug Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital Table 32. Significant Companies of Clinic Table 33. Significant Companies of Home Use Table 34. Global Gastric Motility Disorder Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Gastric Motility Disorder Drug Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Gastric Motility Disorder Drug Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Gastric Motility Disorder Drug Sales Volume Share by Application (2021-2026) Table 38. Global Gastric Motility Disorder Drug Sales Volume Share by Application (2027-2032) Table 39. Global Gastric Motility Disorder Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Gastric Motility Disorder Drug Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Gastric Motility Disorder Drug Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Gastric Motility Disorder Drug Sales Value Share by Application (2021-2026) Table 43. Global Gastric Motility Disorder Drug Sales Value Share by Application (2027-2032) Table 44. Global Gastric Motility Disorder Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Gastric Motility Disorder Drug Sales by Region (2021-2026) & (K Units) Table 46. Global Gastric Motility Disorder Drug Sales Market Share by Region (2021-2026) Table 47. Global Gastric Motility Disorder Drug Sales by Region (2027-2032) & (K Units) Table 48. Global Gastric Motility Disorder Drug Sales Market Share by Region (2027-2032) Table 49. Global Gastric Motility Disorder Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Gastric Motility Disorder Drug Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Gastric Motility Disorder Drug Sales Value Share by Region (2021-2026) Table 52. Global Gastric Motility Disorder Drug Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Gastric Motility Disorder Drug Sales Value Share by Region (2027-2032) Table 54. Global Gastric Motility Disorder Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Gastric Motility Disorder Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Gastric Motility Disorder Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Gastric Motility Disorder Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Gastric Motility Disorder Drug Sales by Country (2021-2026) & (K Units) Table 59. Global Gastric Motility Disorder Drug Sales Market Share by Country (2021-2026) Table 60. Global Gastric Motility Disorder Drug Sales by Country (2027-2032) & (K Units) Table 61. Global Gastric Motility Disorder Drug Sales Market Share by Country (2027-2032) Table 62. Global Gastric Motility Disorder Drug Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Gastric Motility Disorder Drug Sales Value Market Share by Country (2021-2026) Table 64. Global Gastric Motility Disorder Drug Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Gastric Motility Disorder Drug Sales Value Market Share by Country (2027-2032) Table 66. Theravance, Inc. Company Information Table 67. Theravance, Inc. Business Overview Table 68. Theravance, Inc. Gastric Motility Disorder Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Theravance, Inc. Gastric Motility Disorder Drug Product Portfolio Table 70. Theravance, Inc. Recent Development Table 71. Targacept, Inc. Company Information Table 72. Targacept, Inc. Business Overview Table 73. Targacept, Inc. Gastric Motility Disorder Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Targacept, Inc. Gastric Motility Disorder Drug Product Portfolio Table 75. Targacept, Inc. Recent Development Table 76. Helsinn Healthcare S.A. Company Information Table 77. Helsinn Healthcare S.A. Business Overview Table 78. Helsinn Healthcare S.A. Gastric Motility Disorder Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Helsinn Healthcare S.A. Gastric Motility Disorder Drug Product Portfolio Table 80. Helsinn Healthcare S.A. Recent Development Table 81. Concert Pharmaceuticals, Inc. Company Information Table 82. Concert Pharmaceuticals, Inc. Business Overview Table 83. Concert Pharmaceuticals, Inc. Gastric Motility Disorder Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Concert Pharmaceuticals, Inc. Gastric Motility Disorder Drug Product Portfolio Table 85. Concert Pharmaceuticals, Inc. Recent Development Table 86. ChironWells GmbH Company Information Table 87. ChironWells GmbH Business Overview Table 88. ChironWells GmbH Gastric Motility Disorder Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. ChironWells GmbH Gastric Motility Disorder Drug Product Portfolio Table 90. ChironWells GmbH Recent Development Table 91. Key Raw Materials Table 92. Raw Materials Key Suppliers Table 93. Gastric Motility Disorder Drug Distributors List Table 94. Gastric Motility Disorder Drug Customers List Table 95. Research Programs/Design for This Report Table 96. Authors List of This Report Table 97. Secondary Sources Table 98. Primary Sources List of Figures Figure 1. Gastric Motility Disorder Drug Product Image Figure 2. Global Gastric Motility Disorder Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gastric Motility Disorder Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Gastric Motility Disorder Drug Sales (2021-2032) & (K Units) Figure 5. Global Gastric Motility Disorder Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Gastric Motility Disorder Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Ipamorelin Image Figure 10. Velusetrag Image Figure 11. TD-8954 Image Figure 12. Others Image Figure 13. Global Gastric Motility Disorder Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Gastric Motility Disorder Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Gastric Motility Disorder Drug Sales Volume Share by Type (2021-2032) Figure 16. Global Gastric Motility Disorder Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Gastric Motility Disorder Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Gastric Motility Disorder Drug Sales Value Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Home Use Image Figure 22. Global Gastric Motility Disorder Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Gastric Motility Disorder Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Gastric Motility Disorder Drug Sales Volume Share by Application (2021-2032) Figure 25. Global Gastric Motility Disorder Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Gastric Motility Disorder Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Gastric Motility Disorder Drug Sales Value Share by Application (2021-2032) Figure 28. Global Gastric Motility Disorder Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Gastric Motility Disorder Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Gastric Motility Disorder Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Gastric Motility Disorder Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Gastric Motility Disorder Drug Sales Value (2021-2032) & (US$ Million) Figure 33. North America Gastric Motility Disorder Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Gastric Motility Disorder Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Gastric Motility Disorder Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Gastric Motility Disorder Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Gastric Motility Disorder Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Gastric Motility Disorder Drug Sales Value (2021-2032) & (US$ Million) Figure 39. South America Gastric Motility Disorder Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Gastric Motility Disorder Drug Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Gastric Motility Disorder Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Gastric Motility Disorder Drug Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Gastric Motility Disorder Drug Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Ipamorelin
  • Velusetrag
  • TD-8954
  • Others
Applications
  • Hospital
  • Clinic
  • Home Use
Companies covered
  • Theravance, Inc.
  • Targacept, Inc.
  • Helsinn Healthcare S.A.
  • Concert Pharmaceuticals, Inc.
  • ChironWells GmbH

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Gastric Motility Disorder Drug Sales Value (2021-2032)
  4. 1.2.2 Global Gastric Motility Disorder Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Gastric Motility Disorder Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Gastric Motility Disorder Drug Market Dynamics
  1. 2.1 Gastric Motility Disorder Drug Industry Trends
  2. 2.2 Gastric Motility Disorder Drug Industry Drivers
  3. 2.3 Gastric Motility Disorder Drug Industry Opportunities and Challenges
  4. 2.4 Gastric Motility Disorder Drug Industry Restraints
3 Gastric Motility Disorder Drug Market by Company
  1. 3.1 Global Gastric Motility Disorder Drug Company Revenue Ranking in 2025
  2. 3.2 Global Gastric Motility Disorder Drug Revenue by Company (2021-2026)
  3. 3.3 Global Gastric Motility Disorder Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Gastric Motility Disorder Drug Average Price by Company (2021-2026)
  5. 3.5 Global Gastric Motility Disorder Drug Company Ranking (2024-2026)
  6. 3.6 Global Gastric Motility Disorder Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Gastric Motility Disorder Drug Company Product Type and Application
  8. 3.8 Global Gastric Motility Disorder Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Gastric Motility Disorder Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Gastric Motility Disorder Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Gastric Motility Disorder Drug Market by Type
  1. 4.1 Gastric Motility Disorder Drug Type Introduction
  2. 4.1.1 Ipamorelin
  3. 4.1.2 Velusetrag
  4. 4.1.3 TD-8954
  5. 4.1.4 Others
  6. 4.2 Global Gastric Motility Disorder Drug Sales Volume by Type
  7. 4.2.1 Global Gastric Motility Disorder Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Gastric Motility Disorder Drug Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Gastric Motility Disorder Drug Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Gastric Motility Disorder Drug Sales Value by Type
  11. 4.3.1 Global Gastric Motility Disorder Drug Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Gastric Motility Disorder Drug Sales Value by Type (2021-2032)
  13. 4.3.3 Global Gastric Motility Disorder Drug Sales Value Share by Type (2021-2032)
5 Gastric Motility Disorder Drug Market by Application
  1. 5.1 Gastric Motility Disorder Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Home Use
  5. 5.2 Global Gastric Motility Disorder Drug Sales Volume by Application
  6. 5.2.1 Global Gastric Motility Disorder Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Gastric Motility Disorder Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Gastric Motility Disorder Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Gastric Motility Disorder Drug Sales Value by Application
  10. 5.3.1 Global Gastric Motility Disorder Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Gastric Motility Disorder Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Gastric Motility Disorder Drug Sales Value Share by Application (2021-2032)
6 Gastric Motility Disorder Drug Regional Sales and Value Analysis
  1. 6.1 Global Gastric Motility Disorder Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Gastric Motility Disorder Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Gastric Motility Disorder Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Gastric Motility Disorder Drug Sales by Region (2027-2032)
  5. 6.3 Global Gastric Motility Disorder Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Gastric Motility Disorder Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Gastric Motility Disorder Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Gastric Motility Disorder Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Gastric Motility Disorder Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Gastric Motility Disorder Drug Sales Value (2021-2032)
  12. 6.6.2 North America Gastric Motility Disorder Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Gastric Motility Disorder Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Gastric Motility Disorder Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Gastric Motility Disorder Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Gastric Motility Disorder Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Gastric Motility Disorder Drug Sales Value (2021-2032)
  21. 6.9.2 South America Gastric Motility Disorder Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Gastric Motility Disorder Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Gastric Motility Disorder Drug Sales Value Share by Country, 2025 VS 2032
7 Gastric Motility Disorder Drug Country-level Sales and Value Analysis
  1. 7.1 Global Gastric Motility Disorder Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Gastric Motility Disorder Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Gastric Motility Disorder Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Gastric Motility Disorder Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Gastric Motility Disorder Drug Sales by Country (2027-2032)
  6. 7.4 Global Gastric Motility Disorder Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Gastric Motility Disorder Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Gastric Motility Disorder Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Gastric Motility Disorder Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Gastric Motility Disorder Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Gastric Motility Disorder Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Theravance, Inc.
  2. 8.1.1 Theravance, Inc. Company Information
  3. 8.1.2 Theravance, Inc. Business Overview
  4. 8.1.3 Theravance, Inc. Gastric Motility Disorder Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Theravance, Inc. Gastric Motility Disorder Drug Product Portfolio
  6. 8.1.5 Theravance, Inc. Recent Developments
  7. 8.2 Targacept, Inc.
  8. 8.2.1 Targacept, Inc. Company Information
  9. 8.2.2 Targacept, Inc. Business Overview
  10. 8.2.3 Targacept, Inc. Gastric Motility Disorder Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Targacept, Inc. Gastric Motility Disorder Drug Product Portfolio
  12. 8.2.5 Targacept, Inc. Recent Developments
  13. 8.3 Helsinn Healthcare S.A.
  14. 8.3.1 Helsinn Healthcare S.A. Company Information
  15. 8.3.2 Helsinn Healthcare S.A. Business Overview
  16. 8.3.3 Helsinn Healthcare S.A. Gastric Motility Disorder Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Helsinn Healthcare S.A. Gastric Motility Disorder Drug Product Portfolio
  18. 8.3.5 Helsinn Healthcare S.A. Recent Developments
  19. 8.4 Concert Pharmaceuticals, Inc.
  20. 8.4.1 Concert Pharmaceuticals, Inc. Company Information
  21. 8.4.2 Concert Pharmaceuticals, Inc. Business Overview
  22. 8.4.3 Concert Pharmaceuticals, Inc. Gastric Motility Disorder Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Concert Pharmaceuticals, Inc. Gastric Motility Disorder Drug Product Portfolio
  24. 8.4.5 Concert Pharmaceuticals, Inc. Recent Developments
  25. 8.5 ChironWells GmbH
  26. 8.5.1 ChironWells GmbH Company Information
  27. 8.5.2 ChironWells GmbH Business Overview
  28. 8.5.3 ChironWells GmbH Gastric Motility Disorder Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 ChironWells GmbH Gastric Motility Disorder Drug Product Portfolio
  30. 8.5.5 ChironWells GmbH Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Gastric Motility Disorder Drug Value Chain Analysis
  2. 9.1.1 Gastric Motility Disorder Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Gastric Motility Disorder Drug Sales Mode & Process
  6. 9.2 Gastric Motility Disorder Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Gastric Motility Disorder Drug Distributors
  9. 9.2.3 Gastric Motility Disorder Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst